Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 9
2008 5
2009 10
2010 8
2011 19
2012 18
2013 29
2014 34
2015 32
2016 36
2017 52
2018 55
2019 74
2020 72
2021 99
2022 113
2023 103
2024 134
2025 128
2026 73

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

997 results

Results by year

Filters applied: . Clear all
Page 1
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
Zhang X, Liu B, Huang J, Zhang Y, Xu N, Gale RP, Li W, Liu X, Zhu H, Pan L, Yang Y, Lin H, Du X, Liang R, Chen C, Wang X, Li G, Liu Z, Zhang Y, Liu Z, Hu J, Liu C, Li F, Yang W, Meng L, Han Y, Lin L, Zhao Z, Tu C, Zheng C, Bai Y, Zhou Z, Chen S, Qiu H, Yang L, Sun X, Sun H, Zhou L, Liu Z, Wang D, Guo J, Pang L, Zeng Q, Suo X, Zhang W, Zheng Y, Huang X, Jiang Q. Zhang X, et al. Among authors: xu n. Blood. 2024 Oct 31;144(18):1951-1961. doi: 10.1182/blood.2024024761. Blood. 2024. PMID: 39046786 Free PMC article.
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. Among authors: xu n. J Hematol Oncol. 2022 Aug 18;15(1):113. doi: 10.1186/s13045-022-01334-z. J Hematol Oncol. 2022. PMID: 35982483 Free PMC article. Clinical Trial.
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study.
Zhang Y, Zhou H, Suo S, Zhuang J, Yang L, He A, Liu Q, Du X, Gao S, Li Y, Li Y, Chen Y, Wu W, Zhu H, He G, Hong M, Jiang Q, Jiang Z, Jing H, Wang J, Xu N, Yue L, Zheng C, Zhou Z, Jin C, Li X, Liu L, Xu Y, Wu D, Zhang F, Zhang J, Wu L, Yin H, Lv B, Xiao Z, Jin J. Zhang Y, et al. Among authors: xu n. Blood Cancer J. 2024 Dec 18;14(1):216. doi: 10.1038/s41408-024-01202-8. Blood Cancer J. 2024. PMID: 39695117 Free PMC article. Clinical Trial.
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
Ling Y, Xuan L, Xu N, Huang F, Fan Z, Guo Z, Xu X, Liu H, Lin R, Yu S, Zhang H, Jin H, Wu M, Liu C, Liang X, Ou R, Zhang Y, Liu X, Qu H, Zhai X, Sun J, Zhao Y, Liu Q. Ling Y, et al. Among authors: xu n. J Clin Oncol. 2023 Oct 10;41(29):4632-4642. doi: 10.1200/JCO.23.00101. Epub 2023 Jun 19. J Clin Oncol. 2023. PMID: 37335960 Clinical Trial.
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial.
Zhang H, Fan Z, Huang F, Han L, Xu Y, Xu N, Deng L, Wang S, Lin D, Luo X, Zhang Q, Liu X, Li X, Liang X, Xie S, Qu H, Yu S, Zhou H, Shi P, Xuan L, Lin R, Liu H, Jin H, Sun J, Liu Q. Zhang H, et al. Among authors: xu n. J Clin Oncol. 2023 Jan 10;41(2):343-353. doi: 10.1200/JCO.22.00767. Epub 2022 Sep 9. J Clin Oncol. 2023. PMID: 36084276 Free PMC article. Clinical Trial.
Endovascular Therapy Versus Medical Management for Large Ischemic Infarct: 1-Year Outcomes of the ANGEL-ASPECT Trial.
Huo X, Sun D, Nguyen TN, Ma G, Pan Y, Tong X, Yuan G, Han H, Chen W, Wei M, Zhang J, Zhou Z, Yao X, Song W, Cai X, Nan G, Li D, Wang AY, Ling W, Cai C, Wen C, Wang E, Zhang L, Jiang C, Liao G, Chen X, Li T, Liu S, Li J, Sun Y, Xu N, Gao Z, Ju D, Song C, Zhou F, Shi Q, Luo J, Liu Y, Guo Z, Zheng H, Dai L, Zhao J, Geng X, Tang Y, Yin C, Yang H, Zhang X, Li S, Abdalkader M, Gao F, Ma N, Mo D, Ren Z, Liu L, Wang Y, Miao Z; ANGEL-ASPECT Investigators. Huo X, et al. Among authors: xu n. Stroke. 2025 Sep;56(9):2398-2407. doi: 10.1161/STROKEAHA.124.050086. Epub 2025 Aug 25. Stroke. 2025. PMID: 40854041 Clinical Trial.
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.
Jin H, Zhang Y, Yu S, Du X, Xu N, Shao R, Lin D, Chen Y, Xiao J, Sun Z, Deng L, Liang X, Zhang H, Guo Z, Dai M, Shi P, Huang F, Fan Z, Yin Z, Xuan L, Lin R, Jiang X, Yu G, Liu Q. Jin H, et al. Among authors: xu n. J Hematol Oncol. 2023 Apr 29;16(1):42. doi: 10.1186/s13045-023-01437-1. J Hematol Oncol. 2023. PMID: 37120593 Free PMC article. Clinical Trial.
Refractory serositis in Gorham-Stout syndrome.
Di H, Zhang B, Xu N, Yin Y, Han X, Zhang Y, Zeng X. Di H, et al. Among authors: xu n. Orphanet J Rare Dis. 2022 Apr 4;17(1):152. doi: 10.1186/s13023-022-02307-8. Orphanet J Rare Dis. 2022. PMID: 35379268 Free PMC article.
997 results